Foghorn Therapeutics Inc. (FHTX) Tops Q2 EPS by 15c

Foghorn Therapeutics Inc. (NASDAQ: FHTX) reported Q2 EPS of ($0.10), $0.15 better than the analyst estimate of ($0.25). Revenue for the quarter came in at $16.1 million versus the consensus estimate of $7.59 million.

For earnings history and earnings-related data on Foghorn Therapeutics Inc. (FHTX) click here.

You May Also Be Interested In

• ZKH Group Limited (ZKH) Reports Q2 EPS of $0.04
• GE Vernova wins stage 3 contract for Queensland battery project
• Global S&P Futures mixed to up in premarket